Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 16, 2022 at 09:09 am
Share
Daewoong Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 3,029.31 million compared to KRW 2,733.58 million a year ago. Net income was KRW 23,448.54 million compared to KRW 3,160.38 million a year ago. Basic earnings per share from continuing operations was KRW 564 compared to KRW 75 a year ago. Basic earnings per share was KRW 564 compared to KRW 75 a year ago.
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.